HRP930993A2 - Glucagon-like peptide and insulinotropin derivatives - Google Patents

Glucagon-like peptide and insulinotropin derivatives

Info

Publication number
HRP930993A2
HRP930993A2 HR07/899,073A HRP930993A HRP930993A2 HR P930993 A2 HRP930993 A2 HR P930993A2 HR P930993 A HRP930993 A HR P930993A HR P930993 A2 HRP930993 A2 HR P930993A2
Authority
HR
Croatia
Prior art keywords
glucagon
peptide
insulinotropin
derivatives
insulinotropin derivatives
Prior art date
Application number
HR07/899,073A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HRP930993A2 publication Critical patent/HRP930993A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HR07/899,073A 1992-06-15 1993-06-24 Glucagon-like peptide and insulinotropin derivatives HRP930993A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89907392A 1992-06-15 1992-06-15

Publications (1)

Publication Number Publication Date
HRP930993A2 true HRP930993A2 (en) 1996-12-31

Family

ID=25410453

Family Applications (1)

Application Number Title Priority Date Filing Date
HR07/899,073A HRP930993A2 (en) 1992-06-15 1993-06-24 Glucagon-like peptide and insulinotropin derivatives

Country Status (19)

Country Link
EP (2) EP0969016A2 (de)
JP (1) JP2575298B2 (de)
KR (1) KR0154880B1 (de)
CN (1) CN1057098C (de)
AU (1) AU671117B2 (de)
BR (1) BR9306551A (de)
CA (1) CA2138161C (de)
CZ (1) CZ315594A3 (de)
FI (1) FI932722L (de)
HR (1) HRP930993A2 (de)
HU (2) HUT64367A (de)
IL (1) IL105928A0 (de)
MX (1) MX9303554A (de)
NO (1) NO944853D0 (de)
PL (1) PL176007B1 (de)
RU (1) RU2128663C1 (de)
SK (1) SK155694A3 (de)
WO (1) WO1993025579A1 (de)
YU (1) YU41493A (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
AU4415796A (en) * 1994-12-07 1996-06-26 Bionebraska, Inc. Production of c-terminal amidated peptides from recombinant protein constructs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5747453A (en) 1995-06-06 1998-05-05 Alza Corporation Method for increasing the electrotransport flux of polypeptides
US6333189B1 (en) 1996-06-06 2001-12-25 Alza Corporation Method of making an electrotransport device
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE122007000044I2 (de) 1997-01-07 2011-05-05 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
FR2777283B1 (fr) * 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE69941510D1 (de) 1998-08-10 2009-11-19 Us Gov Nat Inst Health Differenzierung von nicht-insulin in insulin-produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
EP1992641A3 (de) * 1998-12-07 2009-07-29 Ipsen Pharma GLP-1-Analoge
CZ295044B6 (cs) * 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EP2213743A1 (de) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albuminfusionsproteine
CA2430934C (en) 2000-12-01 2011-06-21 Takeda Chemical Industries, Ltd. A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
KR20040054729A (ko) * 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
PL209734B1 (pl) 2002-02-20 2011-10-31 Emisphere Tech Inc Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
AU2005203925A1 (en) 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-Like Peptide-1 analogs with long duration of action
HRP20060362A2 (en) 2004-04-23 2007-03-31 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
EP2590997B1 (de) * 2010-07-09 2018-04-04 Dana-Farber Cancer Institute, Inc. Stabilisierte insulinotrope peptide und verfahren zu ihrer verwendung
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
LT3297653T (lt) 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
WO2017210100A1 (en) * 2016-06-02 2017-12-07 Indiana University Research And Technology Corporation Glucagon-like peptide-1-t3 conjugates
LT3541366T (lt) 2016-11-21 2025-03-10 Amylyx Pharmaceuticals, Inc. Eksendino (9-39) buferiniai preparatai
MX2019010651A (es) * 2017-03-08 2020-01-13 Intarcia Therapeutics Inc Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos.
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE193541T1 (de) * 1989-03-20 2000-06-15 Gen Hospital Corp Insulinotropes hormon
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
EP0499990B1 (de) * 1991-02-19 1996-05-15 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung von cysteinfreien Peptiden
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DK39892D0 (da) * 1992-03-25 1992-03-25 Bernard Thorens Peptid

Also Published As

Publication number Publication date
HU211498A9 (en) 1995-11-28
PL176007B1 (pl) 1999-03-31
IL105928A0 (en) 1993-10-20
BR9306551A (pt) 1998-09-15
CN1057098C (zh) 2000-10-04
WO1993025579A1 (en) 1993-12-23
CN1085913A (zh) 1994-04-27
KR950701937A (ko) 1995-05-17
FI932722A7 (fi) 1993-12-16
YU41493A (sh) 1996-10-18
NO944853L (no) 1994-12-14
RU94046251A (ru) 1996-10-27
EP0646128A1 (de) 1995-04-05
CA2138161A1 (en) 1993-12-23
JP2575298B2 (ja) 1997-01-22
HUT64367A (en) 1993-12-28
CZ315594A3 (en) 1995-07-12
FI932722L (fi) 1993-12-16
EP0969016A2 (de) 2000-01-05
SK155694A3 (en) 1995-05-10
AU4027593A (en) 1994-01-04
JPH07504679A (ja) 1995-05-25
KR0154880B1 (ko) 1998-10-15
MX9303554A (es) 1994-06-30
HU9301739D0 (en) 1993-09-28
FI932722A0 (fi) 1993-06-14
RU2128663C1 (ru) 1999-04-10
AU671117B2 (en) 1996-08-15
NO944853D0 (no) 1994-12-14
CA2138161C (en) 2003-10-21

Similar Documents

Publication Publication Date Title
IL105928A0 (en) Glucagon-like peptide and insulinotropin derivatives
HU9600932D0 (en) In-alkyl-n-arylpyrimidinamines and derivatives thereof
GR3023258T3 (en) 3-Aryl-4-hydroxy-delta3-dihydrofuranone and 3-aryl-4-hydroxy-delta3-dihydrothiophenone derivatives
EP0503301A3 (en) Peptide derivatives and application thereof
GB9204769D0 (en) Workcentre and supports
IL107898A0 (en) Dna-armed ribozymes and minizymes
GB9414925D0 (en) Electrode and preparation thereof
GB9211706D0 (en) Peptidyl derivatives
GB9211707D0 (en) Peptidyl derivatives
ZA921279B (en) Substituted alpha-aminoaldehydes and derivatives
GB9204770D0 (en) Workcentre and supports
GB2281830B (en) I/q-modulator and i/q-demodulator
HRP931012A2 (en) Fungicidal 2-imidazoline-5-one and 2-imidazoline-5-thione derivatives
EP0517174A3 (en) Lfa-3 protein and derivatives
IL104472A0 (en) Substituted hexahydro-azepinones and tetrahydro-benzazepinones
ZA949293B (en) Hydrazine derivatives and uses thereof
GB2274507B (en) Handlamps and torches
IL120890A0 (en) Glucagon-like peptide and insulinotropin derivatives
HU9301830D0 (en) Pharmaceutical preparatives containing amidine derivatives and new amidine derivatives
HU9500193D0 (en) Pyridoindolo-benzo-diazepines and derivatives as antipsychotics
NZ248041A (en) Aminoalkyl- tetrahydrofuran derivatives and medicaments
EP0505941A3 (en) Peptifluorin and neopeptifluorin
GB9200826D0 (en) Peptidyl derivatives
ZW5093A1 (en) Sensitizer and use
ZA947921B (en) In-alkyl-n-arylpyrimidinamines and derivatives thereof

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
OBST Application withdrawn